Agios Pharmaceuticals, Inc.
AGIO Healthcare Biotechnology
Agios Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $54.0 million, up 48.0% from fiscal 2024. In the quarter to June 2026, revenue grew 259.3%, EPS grew 12.4% and free cash flow grew 25.0%, each against the same quarter a year earlier. Revenue growth for three consecutive years.
Follow AGIO
Agios Pharmaceuticals, Inc. (AGIO) EV/Sales
As of 16 October 2026, Agios Pharmaceuticals, Inc. (AGIO) trades at a EV/Sales of 12.7×. Over the past ten years it has ranged from 0.1× (June 2022) to 115× (June 2018); the current reading is higher than 18% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 13.4× | (49.76%) |
| FY2024 | 26.7× | 44.83% |
| FY2023 | 18.4× | (63.86%) |
| FY2022 | 50.9× | 328.31% |
| FY2020 | 11.9× | (39.03%) |
| FY2019 | 19.5× | (10.70%) |
| FY2018 | 21.8× | (60.24%) |
| FY2017 | 54.9× | 234.03% |
| FY2016 | 16.5× | (53.97%) |
| FY2015 | 35.7× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 16.2× | (14.67%) |
| Mar 2026 | 19.0× | 41.47% |
| Dec 2025 | 13.4× | (56.55%) |
| Sep 2025 | 30.8× | 27.55% |
| 38 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| LKFT Lakefront Biotherapeutics - Sponsored ADR compare | −2.2× |
| MLYS Mineralys Therapeutics, Inc. compare | n/m |
| SRPT Sarepta Therapeutics, Inc. compare | 1.0× |
| MRVI Maravai LifeSciences Holdings, Inc. compare | 5.3× |
| AGIO Agios Pharmaceuticals, Inc. | 12.7× |
| PVLA Palvella Therapeutics, Inc. compare | 35.6× |
| ZYME Zymeworks Inc. compare | 42.0× |
| IMNM Immunome, Inc. compare | 107× |
| MESO Mesoblast Limited compare | 137× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)